OncoZenge AB (8LY) Stock Statistics & Valuation Metrics

OncoZenge AB has a market cap or net worth of €7.35M. The enterprise value is €81.75M.

OncoZenge AB has 11,713,244 shares outstanding. The number of shares has decreased by -2.65% in one year.

OncoZenge AB’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -87.29%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, OncoZenge AB had revenue of 1.00K and earned -8.69M in profits. Earnings per share was -0.74.

In the last 12 months, operating cash flow was -8.37M and capital expenditures 0.00, giving a free cash flow of -8.37M billion.

OncoZenge AB pays an annual dividend of ―, resulting in a dividend yield of ―

OncoZenge AB upcoming earnings date is ―, ―.

OncoZenge AB as a current ratio of 3.09, with Debt / Equity ratio of 0.00%

In the past 12 months, OncoZenge AB has paid 0.00 in taxes.

OncoZenge AB EV to EBITDA ratio is -4.61, with an EV/FCF ratio of -4.57.

OncoZenge AB has €1.29M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€1.29M billion.

Gross margin is 100.00%, with operating margin of -868500.00%, and net profit margin of -868800.00%.

The average price target for OncoZenge AB is ―, which is 11.43% higher than the current price. The consensus rating is ―